EVOLVERAI
Live / Applied — First extension granted (statement of use) (as of 11 Feb 2026)
What this means for you
Not registered yet, but its 24 Jun 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98614898
- Mark type
- Stylized text
- Filed
- 24 Jun 2024
- Published for opposition
- 17 Jun 2025
- Attorney of record
- Brendan J. Hughes
Goods and services
- Class 009 — Scientific and electric apparatus: Downloadable computer software using artificial intelligence for automated machine learning in the field of drug design and development; Downloadable computer software using artificial intelligence for collecting, analyzing, interpreting, and reporting data and information for drug design and development; Downloadable computer software using artificial intelligence for automated machine learning for drug design and development in the fields of neuroscience and immuno-oncology; Downloadable computer software using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Downloadable computer software using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of neuroscience and immune-oncology; Downloadable computer software for molecular research, research and develop and development of pharmaceutical products and chemical compounds, and analysis of biological or chemical activity in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Downloadable artificial intelligence software for diagnostic and therapeutic use, and for data mining in connection with pharmaceutical drug discovery, development, and response prediction in the fields of neuroscience and immune-oncology; Downloadable software using artificial intelligence and incorporating computational methods and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development.
- Class 042 — Scientific and technological services: Providing online nondownloadable computer software using artificial intelligence for automated machine learning in the field of drug design and development; Providing online nondownloadable computer software using artificial intelligence for collecting, analyzing, interpreting, and reporting data and information for drug design and development; Providing online nondownloadable computer software using artificial intelligence for automated machine learning for drug design and development in the fields of neuroscience and immune-oncology; Providing online nondownloadable computer software using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Providing online nondownloadable computer software using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of neuroscience and immune-oncology; Providing online nondownloadable software for molecular research, research and development of pharmaceutical products and chemical compounds, and analysis of biological or chemical activity in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Providing online nondownloadable artificial intelligence software for diagnostic and therapeutic use, and for data mining in connection with pharmaceutical drug discovery, development, and response prediction in the fields of neuroscience and immuno-oncology; Providing online nondownloadable software using artificial intelligence and incorporating computational methods and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for automated machine learning in the field of drug design and development; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for collecting, analyzing, interpreting, and reporting data and information for drug design and development; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for automated machine learning for drug design and development in the fields of neuroscience and immune-oncology; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of neuroscience and immune-oncology; Platform as a service (PaaS) featuring computer software platforms for molecular research, research and development of pharmaceutical products and chemical compounds, and analysis of biological or chemical activity in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for diagnostic and therapeutic use, and for data mining in connection with pharmaceutical drug discovery, development, and response prediction in the fields of neuroscience and immuno-oncology; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence and incorporating computational methods and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; Pharmaceutical and biopharmaceutical research and development; Pharmaceutical and biopharmaceutical research and development in the fields of neuroscience and immuno-oncology; Scientific and medical research in the fields of pharmaceuticals, biologic testing and interpretation, neuroscience, and immuno-oncology; Research and development of pharmaceuticals, biological preparations, and therapeutic products and medicines.
Owner
- BIOXCEL LLC, New Haven, CT, US
- BIOXCEL LLC, New Haven, CT, US
Prosecution history
- 12 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Feb 2026 — SOU EXTENSION 1 GRANTED
- 11 Feb 2026 — SOU EXTENSION 1 FILED
- 11 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 12 Aug 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Jun 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Jun 2025 — PUBLISHED FOR OPPOSITION
- 11 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 15 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 18 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 18 Apr 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 18 Jan 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 18 Jan 2025 — NON-FINAL ACTION E-MAILED
- 18 Jan 2025 — NON-FINAL ACTION WRITTEN
- 14 Jan 2025 — ASSIGNED TO EXAMINER